| SCIENCE NEWS | Kineta’s ShK-186 Shows Encouraging Early Results as Potential Therapy for Autoimmune Eye Diseases Kineta, Inc. presented encouraging pre-clinical animal results using ShK-186 in a novel ocular formulation as a topical therapy for autoimmune eye disease. [Press release from Kineta, Inc. discussing research presented at the 7th Ocular Diseases Drug Discovery Conference, San Diego] Press Release | Poster Argos Therapeutics Director of Immunology to Present at HIV Vaccines Meeting Dr. Mark DeBenedette, the company’s director of immunology, reviewed immunologic outcomes from a double blind placebo controlled Phase IIb clinical trial of AGS-004, the company’s investigational immunotherapy for the treatment of HIV. [Press release from Argos Therapeutics Inc. discussing research presented at the Keystone Symposium HIV Vaccines Meeting, Banff] Press Release Lycera to Present at the 2015 American Association for Cancer Research Annual Meeting Lycera Corp. announced that the company will present preclinical research from its novel cancer immunotherapy program. [Press release from Lycera Corp. discussing research to be presented at the 2015 American Association for Cancer Research (AACR) Annual Meeting, Philadelphia] Press Release | Abstract Advaxis’s Lm-LLO Immunotherapy Platform to be Featured in Three Poster Presentations Advaxis, Inc. announced that three abstracts revealing new data for Advaxis’s proprietary Lm-LLO cancer immunotherapy platform have been selected for poster presentations. [Press release from Advaxis, Inc. discussing research to be presented at the 2015 American Association for Cancer Research (AACR) Annual Meeting, Philadelphia] Press Release Transgene Announces New Pre-Clinical Data with TG4010 in Combination with Immune Checkpoint Inhibitors and TG3003 (Humanized mAb Anti-CD115) Transgene announced that new pre-clinical data with two of its immunotherapy programs will be presented. [Press release from Transgene discussing research to be presented at the 2015 American Association for Cancer Research (AACR) Annual Meeting, Philadelphia] Press Release RedHill Biopharma to Present at the 3rd Annual Autoimmune & Inflammation Leaders’ Forum Ira Kalfus, MD, RedHill’s Medical Director, will present a case study utilizing therapy targeting Mycobacterium avium paratuberculosis and the study rationale for RedHill’s ongoing RHB-104 Phase III Crohn’s disease development program. [Press release from RedHill Biopharma Ltd. discussing research to be presented at the 3rd Annual Autoimmune & Inflammation Leaders’ Forum, Boston] Press Release From our sponsor: Learn how ex vivo models drive progress in HIV research. Read the research profiles. |
| INDUSTRY NEWS | Celldex Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate the Combination of Varlilumab and MPDL3280A Celldex Therapeutics, Inc. announced that it has entered into a clinical trial collaboration with Roche to evaluate the safety, tolerability and preliminary efficacy of varlilumab, Celldex’s CD27 targeting investigational antibody, and MPDL3280A (anti-PDL1), Roche’s investigational cancer immunotherapy in a Phase I/II study in renal cell carcinoma. [Celldex Therapeutics, Inc.] Press Release A Vaccine against Placental Malaria Made with ExpreS2ion Biotechnologies’ Protein Expression Technology, ExpreS2, Is Ready to Start Human Tests in Germany and Benin ExpreS2ion Biotechnologies announced the release by its partners at University of Copenhagen, of a vaccine candidate against the form of malaria that strikes pregnant women, for testing in humans. [ExpreS2ion Biotechnologies] Press Release Advaxis Announces First Patient Treated in Phase I/II Dose-Escalation Study of ADXS-HPV for Recurrent Cervical Cancer Advaxis, Inc. announced that the first patient was dosed in a Phase I/II clinical trial evaluating higher doses and repeat cycles of ADXS-HPV, an investigational Lm-LLO immunotherapy, for the treatment of patients with recurrent cervical cancer. [Advaxis, Inc.] Press Release Cell Medica Granted Orphan Drug Designation for Novel Cellular Therapy; Treats First Lymphoma Patient in Phase II Trial Cell Medica announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to the company’s cancer immunotherapy treatment, referred to as CMD-003, under development for Epstein-Barr Virus positive non-Hodgkin lymphomas. [Cell Medica] Press Release Immunovaccine Initiates Phase II Clinical Trial of DPX-Survivac Immunotherapy in Recurrent Lymphoma Immunovaccine Inc. announced that it has treated the first patient with diffuse large B cell lymphoma in a Phase II clinical study of its lead cancer immunotherapy DPX-Survivac. [Immunovaccine Inc.] Press Release |
|